Q1 2026 Earnings Estimate for Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Issued By Zacks Research

Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) - Research analysts at Zacks Research decreased their Q1 2026 EPS estimates for shares of Zimmer Biomet in a research report issued on Tuesday, April 2nd. Zacks Research analyst U. Biswas now expects that the medical equipment provider will post earnings per share of $2.25 for the quarter, down from their previous estimate of $2.26. The consensus estimate for Zimmer Biomet's current full-year earnings is $8.07 per share.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share for the quarter, beating the consensus estimate of $2.15 by $0.05. Zimmer Biomet had a net margin of 13.85% and a return on equity of 12.79%. The business had revenue of $1.94 billion for the quarter, compared to analysts' expectations of $1.93 billion. During the same quarter last year, the firm earned $1.88 EPS. The firm's revenue for the quarter was up 6.3% compared to the same quarter last year.

Several other equities analysts have also recently commented on the stock. Citigroup lifted their target price on shares of Zimmer Biomet from $134.00 to $140.00 and gave the stock a "neutral" rating in a research report on Wednesday. Evercore ISI lifted their target price on shares of Zimmer Biomet from $125.00 to $130.00 and gave the stock an "in-line" rating in a research report on Thursday. Raymond James lifted their target price on shares of Zimmer Biomet from $133.00 to $137.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 3rd. Royal Bank of Canada reissued an "outperform" rating and set a $140.00 target price on shares of Zimmer Biomet in a research report on Friday, February 9th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Zimmer Biomet from $115.00 to $125.00 and gave the stock a "neutral" rating in a research report on Friday, February 9th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $139.39.

Zimmer Biomet Stock Down 0.2 %

NYSE ZBH traded down $0.22 during trading hours on Friday, hitting $127.34. The company's stock had a trading volume of 791,725 shares, compared to its average volume of 1,520,502. Zimmer Biomet has a 52 week low of $102.00 and a 52 week high of $149.25. The company has a market capitalization of $26.16 billion, a PE ratio of 26.04, a price-to-earnings-growth ratio of 2.39 and a beta of 1.01. The company has a current ratio of 1.61, a quick ratio of 0.78 and a debt-to-equity ratio of 0.39. The company's 50-day simple moving average is $126.39 and its two-hundred day simple moving average is $118.51.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ZBH. Dodge & Cox lifted its holdings in shares of Zimmer Biomet by 137.7% during the 4th quarter. Dodge & Cox now owns 11,474,535 shares of the medical equipment provider's stock worth $1,396,451,000 after acquiring an additional 6,647,810 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Zimmer Biomet by 19.0% during the 1st quarter. Vanguard Group Inc. now owns 23,102,761 shares of the medical equipment provider's stock worth $2,954,843,000 after acquiring an additional 3,695,510 shares during the last quarter. Norges Bank bought a new stake in shares of Zimmer Biomet during the 4th quarter worth $266,896,000. Moneta Group Investment Advisors LLC lifted its holdings in shares of Zimmer Biomet by 92,041.0% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 1,841,898 shares of the medical equipment provider's stock worth $234,842,000 after acquiring an additional 1,839,899 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of Zimmer Biomet by 18.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,426,866 shares of the medical equipment provider's stock worth $1,147,251,000 after acquiring an additional 1,458,359 shares during the last quarter. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Zimmer Biomet

In other news, VP Chad F. Phipps sold 26,156 shares of the business's stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the completion of the transaction, the vice president now directly owns 44,145 shares in the company, valued at approximately $5,677,929.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.95% of the stock is owned by company insiders.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be paid a $0.24 dividend. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $0.96 dividend on an annualized basis and a yield of 0.75%. Zimmer Biomet's dividend payout ratio is 19.63%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.